These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 33188884)

  • 1. Increased telomerase improves motor function and alpha-synuclein pathology in a transgenic mouse model of Parkinson's disease associated with enhanced autophagy.
    Wan T; Weir EJ; Johnson M; Korolchuk VI; Saretzki GC
    Prog Neurobiol; 2021 Apr; 199():101953. PubMed ID: 33188884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
    Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L
    Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
    Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
    Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treadmill exercise intervention improves gait and postural control in alpha-synuclein mouse models without inducing cerebral autophagy.
    Minakaki G; Canneva F; Chevessier F; Bode F; Menges S; Timotius IK; Kalinichenko LS; Meixner H; Müller CP; Eskofier BM; Casadei N; Riess O; Schröder R; Winkler J; Xiang W; von Hörsten S; Klucken J
    Behav Brain Res; 2019 May; 363():199-215. PubMed ID: 30599154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of autophagy in the brain of transgenic mice with overexpression of А53Т-mutant α-synuclein as an early event at synucleinopathy progression.
    Pupyshev AB; Korolenko TA; Akopyan AA; Amstislavskaya TG; Tikhonova MA
    Neurosci Lett; 2018 Apr; 672():140-144. PubMed ID: 29203207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated accumulation of retinal α-synuclein (pSer129) and tau, neuroinflammation, and autophagic dysregulation in a seeded mouse model of Parkinson's disease.
    Mammadova N; Summers CM; Kokemuller RD; He Q; Ding S; Baron T; Yu C; Valentine RJ; Sakaguchi DS; Kanthasamy AG; Greenlee JJ; Heather West Greenlee M
    Neurobiol Dis; 2019 Jan; 121():1-16. PubMed ID: 30218757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases.
    Spencer B; Potkar R; Trejo M; Rockenstein E; Patrick C; Gindi R; Adame A; Wyss-Coray T; Masliah E
    J Neurosci; 2009 Oct; 29(43):13578-88. PubMed ID: 19864570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase in Brain: The New Kid on the Block and Its Role in Neurodegenerative Diseases.
    Saretzki G; Wan T
    Biomedicines; 2021 Apr; 9(5):. PubMed ID: 33946850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease.
    Haggerty T; Credle J; Rodriguez O; Wills J; Oaks AW; Masliah E; Sidhu A
    Eur J Neurosci; 2011 May; 33(9):1598-610. PubMed ID: 21453448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.
    Butkovich LM; Houser MC; Chalermpalanupap T; Porter-Stransky KA; Iannitelli AF; Boles JS; Lloyd GM; Coomes AS; Eidson LN; De Sousa Rodrigues ME; Oliver DL; Kelly SD; Chang J; Bengoa-Vergniory N; Wade-Martins R; Giasson BI; Joers V; Weinshenker D; Tansey MG
    J Neurosci; 2020 Sep; 40(39):7559-7576. PubMed ID: 32868457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.
    Crews L; Spencer B; Desplats P; Patrick C; Paulino A; Rockenstein E; Hansen L; Adame A; Galasko D; Masliah E
    PLoS One; 2010 Feb; 5(2):e9313. PubMed ID: 20174468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model.
    Wang W; Song N; Jia F; Tang T; Bao W; Zuo C; Xie J; Jiang H
    Neurochem Int; 2018 Mar; 114():71-79. PubMed ID: 29355568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.
    McLean JR; Hallett PJ; Cooper O; Stanley M; Isacson O
    Mol Cell Neurosci; 2012 Feb; 49(2):230-9. PubMed ID: 22155155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Intervention Targeting FAF1 Restores Autophagic Flux for α-Synuclein Degradation in the Brain of a Parkinson's Disease Mouse Model.
    Kim BS; Song JA; Jang KH; Jang T; Jung B; Yoo SE; Lee JM; Kim E
    ACS Chem Neurosci; 2022 Mar; 13(6):806-817. PubMed ID: 35230076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.
    Fleming SM; Mulligan CK; Richter F; Mortazavi F; Lemesre V; Frias C; Zhu C; Stewart A; Gozes I; Morimoto B; Chesselet MF
    Mol Cell Neurosci; 2011 Mar; 46(3):597-606. PubMed ID: 21193046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease.
    Alvarez-Erviti L; Seow Y; Schapira AH; Rodriguez-Oroz MC; Obeso JA; Cooper JM
    Cell Death Dis; 2013 Mar; 4(3):e545. PubMed ID: 23492776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease.
    Matrone C; Dzamko N; Madsen P; Nyegaard M; Pohlmann R; Søndergaard RV; Lassen LB; Andresen TL; Halliday GM; Jensen PH; Nielsen MS
    PLoS One; 2016; 11(8):e0160501. PubMed ID: 27509067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.